Abstract:Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) induced Coronavirus Disease - 19 (COVID-19) cases have been increasing at an alarming rate (7.4 million positive cases as on June 11 2020), causing high mortality (4,17,956 deaths as on June 11 2020) and economic loss (a 3.2% shrink in global economy in 2020) across 212 countries globally. The clinical manifestations of this disease are pneumonia, lung injury, inflammation, and severe acute respiratory syndrome (SARS). Currently, there is no vaccine or effective pharmacological agents available for the prevention/treatment of SARS-CoV2 infections. Moreover, development of a suitable vaccine is a challenging task due to antibody-dependent enhancement (ADE) and Th-2 immunopathology, which aggravates infection with SARS-CoV-2. Furthermore, the emerging SARS-CoV-2 strain exhibits several distinct genomic and structural patterns compared to other coronavirus strains, making the development of a suitable vaccine even more difficult. Therefore, the identification of novel small molecule inhibitors (NSMIs) that can interfere with viral entry or viral propagation is of special interest and is vital in managing already infected cases. SARS-CoV-2 infection is mediated by the binding of viral Spike proteins (S-protein) to human cells through a 2-step process, which involves Angiotensin Converting Enzyme-2 (ACE2) and Transmembrane Serine Protease (TMPRSS)-2. Therefore, the development of novel inhibitors of ACE2/TMPRSS2 is likely to be beneficial in combating SARS-CoV-2 infections. However, the usage of ACE-2 inhibitors to block the SARS-CoV-2 viral entry requires additional studies as there are conflicting findings and severe health complications reported for these inhibitors in patients. Hence, the current interest is shifted toward the development of NSMIs, which includes natural antiviral phytochemicals and Nrf-2 activators to manage a SARS-CoV-2 infection. It is imperative to investigate the efficacy of existing antiviral phytochemicals and Nrf-2 activators to mitigate the SARS-CoV-2-mediated oxidative stress. Therefore, in this review, we have reviewed structural features of SARS-CoV-2 with special emphasis on key molecular targets and their known modulators that can be considered for the development of NSMIs.

Targeting SARS-CoV-2 entry processes: The promising potential and future of host-targeted small-molecule inhibitors

Potential Therapeutic Approaches for the Early Entry of SARS-CoV-2 by Interrupting the Interaction Between the Spike Protein on SARS-CoV-2 and Angiotensin-Converting Enzyme 2 (ACE2)

SARS-CoV-2 Cell Entry and Targeted Antiviral Development

Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules

Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.

Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2

SARS-CoV-2 Entry Inhibitors Targeting Virus-ACE2 or Virus-TMPRSS2 Interactions

Recent advances in developing small-molecule inhibitors against SARS-CoV-2

An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies

Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy

Recent advances in small-molecular therapeutics for COVID-19

Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors—The Current Status

Small molecules in the treatment of COVID-19

Potential Therapeutic Targets and Promising Drugs for Combating SARS‐CoV‐2

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection

An update review of emerging small-molecule therapeutic options for COVID-19

Development of SARS-CoV-2 Entry Antivirals

Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies

SARS-CoV-2–host cell surface interactions and potential antiviral therapies

Harnessing host enhancers of SARS-CoV-2 entry as novel targets for antiviral therapy